ROBIN PARIHAR to Receptor, ErbB-2
This is a "connection" page, showing publications ROBIN PARIHAR has written about Receptor, ErbB-2.
Connection Strength
0.204
-
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res. 2004 Aug 01; 10(15):5027-37.
Score: 0.045
-
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol. 2003 Apr 15; 170(8):4242-53.
Score: 0.041
-
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest. 2002 Oct; 110(7):983-92.
Score: 0.040
-
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 03 19; 4(1):368.
Score: 0.036
-
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-? production. J Immunol. 2011 Mar 15; 186(6):3401-9.
Score: 0.018
-
Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol. 2006 Jul 01; 177(1):120-9.
Score: 0.013
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
Score: 0.010